Osteomyelitis - Pipeline Review, H1 2019

Global Markets Direct’s, ‘Osteomyelitis - Pipeline Review, H1 2019’, provides an overview of the Osteomyelitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Osteomyelitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Osteomyelitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Osteomyelitis

- The report reviews pipeline therapeutics for Osteomyelitis by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Osteomyelitis therapeutics and enlists all their major and minor projects

- The report assesses Osteomyelitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Osteomyelitis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Osteomyelitis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Osteomyelitis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Allergan Plc

Debiopharm International SA

Motif Bio Plc

Nabriva Therapeutics Plc

Telephus Medical LLC

Allergan Plc

Debiopharm International SA

Motif Bio Plc

Nabriva Therapeutics Plc

Telephus Medical LLC

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Osteomyelitis – Overview

Osteomyelitis – Therapeutics Development

Pipeline Overview

Pipeline by Companies ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Osteomyelitis – Overview

Osteomyelitis – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Osteomyelitis – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Osteomyelitis – Companies Involved in Therapeutics Development

Allergan Plc

Debiopharm International SA

Motif Bio Plc

Nabriva Therapeutics Plc

Telephus Medical LLC

Osteomyelitis – Drug Profiles

afabicin – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ceforanide – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dalbavancin – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs for Bone Cancer and Osteomyelitis – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lefamulin – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MTF-101 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TPH-101 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Osteomyelitis – Dormant Projects

Osteomyelitis – Product Development Milestones

Featured News & Press Releases

Apr 12, 2018: Cardiome Announces Xydalba Abstracts at ECCMID 2018

Dec 11, 2017: Telephus Biosciences Appoints Patrick Vink, M.D., MBA, William Boyle, Ph.D., and Richard Proctor, M.D., as Company Advisors

Oct 24, 2016: Allergan to Present New Data on DALVANCE (dalbavancin) at IDWeek 2016 in New Orleans

Apr 08, 2016: Debiopharm International to present the latest findings on Debio 1450 at ECCMID

Oct 10, 2014: Durata Therapeutics Presents New Data for DALVANCE(TM) at IDWeek 2014

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Osteomyelitis, H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by ...

List of Tables

Number of Products under Development for Osteomyelitis, H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Osteomyelitis – Pipeline by Allergan Plc, H1 2019

Osteomyelitis – Pipeline by Debiopharm International SA, H1 2019

Osteomyelitis – Pipeline by Motif Bio Plc, H1 2019

Osteomyelitis – Pipeline by Nabriva Therapeutics Plc, H1 2019

Osteomyelitis – Pipeline by Telephus Medical LLC, H1 2019

Osteomyelitis – Dormant Projects, H1 2019

List of Figures

List of Figures

Number of Products under Development for Osteomyelitis, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by ...

List of Figures

Number of Products under Development for Osteomyelitis, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Targets, H1 2019

Number of Products by Stage and Targets, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports